Rhythm Pharmaceuticals said it is beginning a midstage trial to assess the safety and efficacy of its experimental drug RM-493 on weight reduction, as well as its effect on glucose and insulin resistance in obese patients. RM-493 is a melanocortin 4 receptor agonist.
Rhythm's experimental obesity drug enters midstage development
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|